Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Brynskov

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Alimentary Pharmacology & Therapeutics|August 7, 2012
Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's diseaseC Steenholdt, C Enevold, M A Ainsworth, et al.
Gut|June 22, 2002
Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel diseaseJ Brynskov, P Foegh, G Pedersen, et al.
Alimentary Pharmacology & Therapeutics|May 9, 2013
Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel diseaseC Steenholdt, Y Palarasah, K Bendtzen, et al.
Lancet (London, England)|April 1, 1989
Treatment of refractory ulcerative colitis with cyclosporin enemasJ Brynskov, L Freund, O O Thomsen, et al.
Alimentary Pharmacology & Therapeutics|August 14, 2013
Commentary: antibodies reacting with the infliximab Fab portion--something new? Authors' replyC H Nielsen, C Steenholdt, Y Palarasah, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|April 30, 2004
Immunoassays of human trefoil factors 1 and 2: measured on serum from patients with inflammatory bowel diseaseE M Vestergaard, J Brynskov, K Ejskjaer, et al.
The Cochrane Database of Systematic Reviews|April 23, 2005
Cyclosporine for induction of remission in Crohn's diseaseJ W D McDonald, B G Feagan, D Jewell, et al.
Alimentary Pharmacology & Therapeutics|April 1, 1989
Low-dose cyclosporin for Crohn's disease: implications for clinical trialsJ Brynskov, V Binder, P Riis, et al.
Transplantation Proceedings|June 1, 1988
Cyclosporine in inflammatory bowel diseaseJ Brynskov, V Binder, P Riis, et al.
The New England Journal of Medicine|September 28, 1989
A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's diseaseJ Brynskov, L Freund, S N Rasmussen, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Alimentary Pharmacology & Therapeutics|August 7, 2012
Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's diseaseC Steenholdt, C Enevold, M A Ainsworth, et al.
Gut|June 22, 2002
Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel diseaseJ Brynskov, P Foegh, G Pedersen, et al.
Alimentary Pharmacology & Therapeutics|May 9, 2013
Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel diseaseC Steenholdt, Y Palarasah, K Bendtzen, et al.
Lancet (London, England)|April 1, 1989
Treatment of refractory ulcerative colitis with cyclosporin enemasJ Brynskov, L Freund, O O Thomsen, et al.
Alimentary Pharmacology & Therapeutics|August 14, 2013
Commentary: antibodies reacting with the infliximab Fab portion--something new? Authors' replyC H Nielsen, C Steenholdt, Y Palarasah, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|April 30, 2004
Immunoassays of human trefoil factors 1 and 2: measured on serum from patients with inflammatory bowel diseaseE M Vestergaard, J Brynskov, K Ejskjaer, et al.
The Cochrane Database of Systematic Reviews|April 23, 2005
Cyclosporine for induction of remission in Crohn's diseaseJ W D McDonald, B G Feagan, D Jewell, et al.
Alimentary Pharmacology & Therapeutics|April 1, 1989
Low-dose cyclosporin for Crohn's disease: implications for clinical trialsJ Brynskov, V Binder, P Riis, et al.
Transplantation Proceedings|June 1, 1988
Cyclosporine in inflammatory bowel diseaseJ Brynskov, V Binder, P Riis, et al.
The New England Journal of Medicine|September 28, 1989
A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's diseaseJ Brynskov, L Freund, S N Rasmussen, et al.
Pageof 8